# Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

> **NCT00920907** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 99 (actual)

## Conditions studied

- Advanced Melanoma

## Interventions

- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT00920907
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-04
- **Final completion:** 2012-10
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2014-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920907, "Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00920907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*